Hormonal
Once-weekly semaglutide (1.0 mg) and once-daily liraglutide (up to 1.8 mg) significantly reduce albuminuria and slow the decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes, with effects being more pronounced in patients with preexisting chronic kidney disease (eGFR <60 mL/min/1.73 m2).
If you have type 2 diabetes, especially if you have early signs of kidney stress (like reduced eGFR or albuminuria), GLP-1 receptor agonists like semaglutide (once weekly) or liraglutide (once daily) can protect your kidneys. They reduce protein in the urine (albuminuria) and slow the loss of kidney function over time. This benefit is particularly strong if your kidney function is already reduced (eGFR <60). Discuss these options with your doctor, as they may offer kidney protection beyond just blood sugar control.
In the pooled analysis, semaglutide/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo... With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed... Effects appeared larger in patients with baseline eGFR <60 versus ≥60 mL/min/1.73 m2
Why this rating
Pooled analysis of two large, randomized, double-blinded, placebo-controlled trials (SUSTAIN 6 and LEADER) with over 12,000 patients provides high-quality evidence, though it is a post hoc analysis of secondary outcomes.
Source
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman et al. · Circulation · 2021
DOI 10.1161/circulationaha.121.055459
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →